m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00604
 [1], [2], [3]
m6A modification MIR320A MIR320A METTL3 Methylation : m6A sites Indirect Inhibition RNA modification CTNNB1 CTNNB1 YBX1 : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-mir-320a
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> 5-methylcytidine (m5C)
Epigenetic Regulator Y-box-binding protein 1 (YBX1) READER View Details
Regulated Target Catenin beta-1 (CTNNB1/Beta-catenin) View Details
Crosstalk Relationship m6A  →  m5C Inhibition
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary METTL3 interacts with hsa-mir-320a, reading its m6A level and inhibiting its physical interaction with Catenin beta-1 (CTNNB1/Beta-catenin), which was regulated by YBX1-mediated m5C modification.
In-vitro Model
 MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Catenin beta-1 (CTNNB1/Beta-catenin) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Recombinant human endostatin Approved [4]
Synonyms
Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05YAG
 Compound Name CEQ-508 Phase 1/2 [5]
Synonyms
CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina
    Click to Show/Hide
External Link
TTD: D00GBZ
 Compound Name C 82 Phase 1/2 [6]
Synonyms
N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 75202656
TTD: D0DA5M
 Compound Name Tegavivint Phase 1 [7]
Synonyms
1227637-23-1; 18AP231HUP; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; AKOS032946684; BC2059; BC-2059; BDBM50108103; BS-14778; CHEMBL3601411; CS-0039507; D71173; HY-109103; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; NSC785527; NSC-785527; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; SCHEMBL14947676; Tegatrabetan; Tegavivint; Tegavivint [INN]; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46212391
TTD: D54WUR
References
Ref 1 Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. Cancer Lett. 2019 Jun 28;452:119-131. doi: 10.1016/j.canlet.2019.03.014. Epub 2019 Mar 21.
Ref 2 m(6)A Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells. Mol Ther Nucleic Acids. 2020 Mar 6;19:421-436. doi: 10.1016/j.omtn.2019.12.001. Epub 2019 Dec 12.
Ref 3 LncRNA DANCR and miR-320a suppressed osteogenic differentiation in osteoporosis by directly inhibiting the Wnt/beta-catenin signaling pathway. Exp Mol Med. 2020 Aug;52(8):1310-1325. doi: 10.1038/s12276-020-0475-0. Epub 2020 Aug 11.
Ref 4 Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/Beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. doi: 10.1371/journal.pone.0107463. eCollection 2014.
Ref 5 Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 Tegavivint and the beta-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227.